DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Key Points

• Results missed expectations: DENTSPLY SIRONA reported earnings of $0.29 per share versus the $0.31 consensus, while quarterly revenue of $836 million also came in below estimates of $861.68 million.
• 2026 guidance was cut: The company now expects adjusted EPS of $1.20–$1.30, down from $1.40–$1.50, and sales of approximately $3.5 billion, compared with its prior range of $3.5–$3.6 billion.
• Operating cash flow fell to $32 million from $79 million, largely due to unfavorable working capital; management said reducing debt remains a priority.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.02), FiscalAI reports. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The business had revenue of $836.00 million during the quarter, compared to analysts' expectations of $861.68 million. DENTSPLY SIRONA updated its FY 2026 guidance to 1.200-1.300 EPS.

Here are the key takeaways from DENTSPLY SIRONA's conference call:

• DENTSPLY SIRONA lowered its 2026 outlook: sales are now expected to be approximately $3.5 billion, and adjusted EPS $1.20–$1.30, down from prior ranges of $3.5–$3.6 billion and $1.40–$1.50, respectively.
• Q3 revenue fell 7% in constant currency to $836 million, and adjusted EPS declined to $0.29 from $0.42 a year ago. Dental businesses faced lower volumes, planned dealer inventory reductions, and pressure in EMEA.
• Operating cash flow decreased to $32 million from $79 million, primarily due to unfavorable working capital; net debt to EBITDA was 3.4, and management said debt reduction remains a priority.
• Q3 results included a $39 million pre-tax accounting benefit from refining estimates of intercompany profit in inventory transfers; management said it reflects multiple years, is not expected to recur, and is included in the updated EPS outlook.
• Management cited early growth areas, including record Wellspect sales, up 10%, double-digit U.S. growth in MIS implants, and a return to growth in U.S. endodontics. It is expanding sales coverage and clinical education, while cautioning that broader, sustained improvement is still needed.

DENTSPLY SIRONA Stock Down 5.3%

XRAY stock traded down $0.56 during midday trading on Thursday, hitting $10.09. The company's stock had a trading volume of 7,842,097 shares, compared to its average volume of 4,910,097. The company has a market cap of $2.01 billion, a PE ratio of -3.67, a P/E/G ratio of 1.25 and a beta of 0.87. DENTSPLY SIRONA has a 12 month low of $8.32 and a 12 month high of $14.76. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. The firm's 50-day moving average is $9.65 and its 200-day moving average is $11.30.

Wall Street Analyst Weigh In

XRAY has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Friday, October 30th. Barrington Research dropped their target price on DENTSPLY SIRONA from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Monday, October 26th. BMO Capital Markets cut their target price on DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating on the stock in a research note on Thursday, September 17th. Piper Sandler reduced their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Friday, October 9th. Finally, Leerink Partners lowered their price target on DENTSPLY SIRONA from $14.00 to $10.00 and set a "market perform" rating for the company in a research report on Wednesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $12.62.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.